ANVS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
14.4M
-20.2%
18.0M
+85.6%
9.7M
+30.5%
7.4M
+18.6%
6.3M
R&D
12.0M
-28.2%
16.7M
+91.1%
8.8M
+39.1%
6.3M
+21.9%
5.2M
SG&A
2.4M
+83.5%
1.3M
+35.2%
955.2K
-16.5%
1.1M
+3.1%
1.1M
Operating Income
-14377712
+20.2%
-18012182
-85.6%
-9706149
-30.5%
-7434975
-18.6%
-6271453
EBITDA
-14377712
+20.2%
-18012182
-85.6%
-9706149
-30.5%
-7434975
-18.6%
-6271453
Net Income
-14820815
+15.8%
-17606382
-79.0%
-9834412
-35.4%
-7262658
-16.8%
-6220058
EPS (Basic)
$-0.40
+36.5%
$-0.63
-65.8%
$-0.38
-2.7%
$-0.37
-15.6%
$-0.32
EPS (Diluted)
$-0.40
+36.5%
$-0.63
-65.8%
$-0.38
-2.7%
$-0.37
-15.6%
$-0.32
Shares (Diluted)
37.5M
+34.7%
27.8M
+8.8%
25.6M
+30.1%
19.7M
+1.0%
19.5M
Annovis Bio (ANVS) โ€” Financials